LB Pharmaceuticals Stock (NASDAQ:LBRX)


OwnershipChart

Previous Close

$19.70

52W Range

$13.36 - $23.15

50D Avg

$17.02

200D Avg

$16.65

Market Cap

$533.07M

Avg Vol (3M)

$182.19K

Beta

-

Div Yield

-

LBRX Company Profile


Clinical‑stage biopharmaceutical company developing novel therapies for neuropsychiatric diseases (e.g. schizophrenia, bipolar depression). Lead candidate is LB‑102, a methylated derivative of amisulpride.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

16

IPO Date

Sep 11, 2025

Website

LBRX Performance


Peer Comparison


TickerCompany
AUTLAutolus Therapeutics plc
DSGNDesign Therapeutics, Inc.
ALTAltimmune, Inc.
ANNXAnnexon, Inc.
LRMRLarimar Therapeutics, Inc.
SLDBSolid Biosciences Inc.
RCKTRocket Pharmaceuticals, Inc.
DBVTDBV Technologies S.A.
AURAAura Biosciences, Inc.
KRROKorro Bio, Inc.